The Triangle is now home to a new contract research services firm.

Triangle Research Labs is a joint venture between The Hamner Institutes for Health Sciences and PBM Capital Group, which is based in Virginia.

The new firm is based at The Hamner complex in RTP.

A group of four Hamner scientists and their support group are now part of that company.

PBM Capital is staffing it with personnel relocated from a subsidiary, GigaCyte, which is based in Connecticut.

The focus of the company is predictive toxicity testing for biopharma firms developing new drugs. Other tests will focus on drug metabolism, drug-drug interactions, in vivo pharmacokinetics and toxicology, drug characterization, diabetes research, virology, and neural toxicology, among others.

Dr. Ivin Silver, a former executive with GlaxoSmithKline, will lead the company along with Shiloh Barfield, a former vice rpesident of sales and marketing at CellzDirect. Silver was director of drug, metabolism and pharmacokinetics at GSK.

Dr. Edward LeCluyse, a senior investigator at The Hamner’s Institute for Chemical Safety Sciences, will supervise research and development programs.

“This partnership with PBM Capital Group aligns quite well with our shared vision to advance global public health,” said William Greenlee, The Hamner’s xhiec executive officer. “We are delighted that The Hamner will be the home for Triangle Research Labs, and I look forward to the many breakthroughs that will transform predictive drug safety models and accelerate new medicine development.”

The company’s staff includes specialists in cell culture, drug metabolism, mass spectrometry, stem cell development, analytical chemistry and other fields.

GigaqCyte will continue to operate a cell products division.

“We are pleased to have the opportunity to work in close collaboration with The Hamner on a partnership that we believe will benefit both of us, as well as the field of predictive toxicity testing,” said Paul Manning, CEO of PBM Capital Group, in a statement. “The Hamner’s reputation for scientific excellence is well known, and we are privileged to be associated with them. It is our belief that this research collaboration will lead to innovative science and advances in developing and gaining adoption of the next generation of predictive tools to aid in chemical toxicology and drug discovery and development.”

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.